No Data
No Data
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November
Alterity Therapeutics (ASX:ATH) said the second phase of its ATH434-201 study is on track for completion in November after receiving the greenlight from an independent Data Monitoring Committee, accor
Press Release: Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (AS
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund
Alterity Therapeutics (ASX:ATH) received a AU$3.9 million research and development tax incentive refund for eligible activities for the year ended June 30, 2023. The rebate will be used for clinical t
Alterity Therapeutics Price Target Maintained With a $4.00/Share by Benchmark
Alterity Therapeutics Price Target Maintained With a $4.00/Share by Benchmark
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%
Alterity Therapeutics (ASX:ATH) secured binding commitments to raise about AU$3.3 million via a share placement priced at AU$0.0038 apiece. Proceeds will fund the biotechnology company's clinical tria
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation
Alterity Therapeutics (ASX:ATH) advanced its phase two trial evaluating the use of the ATH434-201 medication in patients with an early onset of multiple system atrophy. The move was made following rec
No Data